Celularity (CELU)
NASDAQ:CELU
Want to see CELU full AI Analyst Report?
Top Page
Celularity
(NASDAQ:CELU)
Select Model
Select Model
Rating:42Neutral
Price Target:
$0.78
▼(-37.92% Downside)
Action:Reiterated
Date:05/01/26
The score is primarily held down by weak financial performance—continued losses, negative equity, and ongoing cash burn—along with bearish technicals showing a strong downtrend and negative momentum. Valuation support is limited due to negative earnings and no dividend yield data, while the recent licensing transaction is a modest offset that could improve funding and reduce costs if it closes as described.
Positive Factors
Focused cell-therapy platform
Celularity’s core business is a differentiated allogeneic cell-therapy platform derived from placental and umbilical tissues. This unique biological source and multi-program pipeline (NK cells, stromal-like cells) support scalable manufacturing, platform IP, and durable competitive positioning in regenerative medicine.
Negative Factors
Negative equity and leverage
Negative equity and elevated leverage materially weaken financial flexibility and raise refinancing and dilution risk. With equity below zero, access to favorable financing or strategic transactions is constrained, creating a persistent balance-sheet overhang that limits strategic optionality over the coming months.
Read all positive and negative factors
Positive Factors
Negative Factors
Focused cell-therapy platform
Celularity’s core business is a differentiated allogeneic cell-therapy platform derived from placental and umbilical tissues. This unique biological source and multi-program pipeline (NK cells, stromal-like cells) support scalable manufacturing, platform IP, and durable competitive positioning in regenerative medicine.
Read all positive factors
Celularity (CELU) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$23.40M
Dividend YieldN/A
Average Volume (3M)206.82K
Price to Earnings (P/E)―
Beta (1Y)2.97
Revenue Growth-51.03%
EPS Growth-35.20%
CountryUS
Employees120
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-3.69
Shares Outstanding28,945,961
10 Day Avg. Volume277,262
30 Day Avg. Volume206,824
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-0.75
Price to Sales (P/S)1.07
P/FCF Ratio-2.14
Enterprise Value/Market Cap2.31
Enterprise Value/Revenue2.03
Enterprise Value/Gross Profit2.67
Enterprise Value/Ebitda-0.69
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-2.75
Revenue Forecast (FY)$44.00M
Celularity Business Overview & Revenue Model
Company Description
Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerativ...
How the Company Makes Money
null...
Celularity Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
22
Negative
Cash Flow
28
Negative
| Breakdown | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 26.55M | 54.22M | 22.77M | 17.98M | 21.34M |
| Gross Profit | 20.19M | 39.23M | 6.75M | -1.69M | 11.68M |
| EBITDA | -77.66M | -43.71M | -183.95M | -138.83M | -88.11M |
| Net Income | -91.80M | -57.89M | -196.29M | 14.19M | -100.12M |
Balance Sheet | |||||
| Total Assets | 107.33M | 132.68M | 143.89M | 401.07M | 414.13M |
| Cash, Cash Equivalents and Short-Term Investments | 6.17M | 738.00K | 227.00K | 13.97M | 37.24M |
| Total Debt | 40.90M | 68.84M | 65.42M | 65.59M | 31.14M |
| Total Liabilities | 145.39M | 123.84M | 102.93M | 202.16M | 314.71M |
| Stockholders Equity | -38.06M | 8.84M | 40.96M | 198.90M | 99.42M |
Cash Flow | |||||
| Free Cash Flow | -13.25M | -6.56M | -42.73M | -143.11M | -116.30M |
| Operating Cash Flow | -13.25M | -6.40M | -38.69M | -137.88M | -110.10M |
| Investing Cash Flow | 0.00 | 514.00K | -4.05M | -5.24M | -5.90M |
| Financing Cash Flow | 18.65M | 6.70M | 24.09M | 119.84M | 98.56M |
Celularity Technical Analysis
Negative
1.25
Price Trends
1.27
Negative
1.37
Negative
1.92
Negative
Market Momentum
>-0.01
Positive
43.98
Neutral
3.10
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CELU, the sentiment is Negative. The current price of 1.25 is below the 20-day moving average (MA) of 1.28, below the 50-day MA of 1.27, and below the 200-day MA of 1.92, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 43.98 is Neutral, neither overbought nor oversold. The STOCH value of 3.10 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CELU.
Celularity Risk Analysis
Celularity disclosed 76 risk factors in its most recent earnings report. Celularity reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Celularity Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $480.02M | -12.22 | -60.73% | ― | -78.29% | 54.16% | |
46 Neutral | $35.50M | -1.16 | -1.04% | ― | ― | 21.67% | |
42 Neutral | $23.40M | -0.29 | 763.31% | ― | -51.03% | -35.20% | |
42 Neutral | $5.47M | -0.15 | -1292.87% | ― | ― | -72.78% |
* Healthcare Sector Average
CELU
Celularity
0.81
-1.36
-62.76%
LTRN
Lantern Pharma
3.14
-0.44
-12.29%
STTK
Shattuck Labs
6.26
5.21
496.19%
FBLG
FibroBiologics, Inc.
1.05
-17.17
-94.24%
Celularity Corporate Events
Business Operations and StrategyExecutive/Board ChangesM&A TransactionsPrivate Placements and FinancingRegulatory Filings and Compliance
Celularity Closes NexGel Asset Sale, Refocuses on Cell Therapy
Neutral
Apr 21, 2026
On April 17, 2026, Celularity amended its asset purchase and exclusive license agreement with NexGel, confirming total consideration of $13.3 million, including $8.3 million in cash at commencement and a $5.0 million convertible note, and revising...
Business Operations and StrategyM&A Transactions
Celularity Licenses Biomaterials Portfolio to NexGel Partner
Positive
Mar 10, 2026
On March 6, 2026, Celularity entered an asset purchase and exclusive license agreement with NexGel granting exclusive rights to its commercial-stage biomaterials portfolio and certain development programs, for consideration of up to $35 million in...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.